Electroporation instruments are medical devices used to introduce molecules such as drugs, DNA, RNA or proteins into cells and tissues using an electrical pulse. The procedure temporarily or reversibly creates nanopores in the cell membrane. Electroporation instruments find application in research, drug delivery and gene therapy. They offer high transfection efficiency with minimal toxicity.
The global electroporation instruments market is estimated to be valued at US$ 242.41 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing adoption of electroporation-based therapies: Currently, electroporation based therapies for cancer and DNA vaccines are gaining momentum. Companies are investing significantly in research and development of electroporation based therapies which is driving the demand for electroporation instruments. For instance, clinical trials are ongoing to evaluate the safety and efficacy of electrochemotherapy and gene electrotransfer based therapies for various cancers like melanoma, breast cancer and head & neck cancer. Widespread adoption of these therapies is expected to boost the growth of electroporation instruments market during the forecast period.
Segment Analysis
The global electroporation instruments market is dominated by laboratory electroporation systems sub-segment. Laboratory electroporation systems accounted for the highest market share in 2022 owing to wide scale adoption of these systems in research activities conducted at academic institutes and biotech & pharmaceutical companies for gene delivery techniques. These systems find extensive usage in applications such as DNA and RNA transfection, protein delivery, cell fusion, and molecular biology applications.
Key Takeaways
The Global Electroporation Instruments Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The global electroporation instruments market is estimated to be valued at US$ 242.41 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030.
North America is currently the largest regional market for electroporation instruments. The presence of prominent life science research institutes and biotech companies conducting extensive research has contributed to North America emerging as the fastest growing regional market. North America is expected to maintain its dominance over the forecast period owing to increasing R&D investments in cell therapeutics and genetic engineering research by pharmaceutical and biotechnology companies in the region. The rising prevalence of chronic diseases and growing focus on developing advanced cell-based therapies provide an impetus to the adoption of electroporation instruments in the region.
Key players
Key players operating in the electroporation instruments market are Bio-Rad Laboratories, Inc, Thermo Fisher Scientific Inc., BTX ( a division of Harvard Bioscience), Celetrix, LLC., Gamma Biosciences, Merck KgaA, Eppendorf SE, MaxCyte, Inc. BEX CO.,LTD., Lonza, Altogen Biosystems, Ala Scientific Instruments, Inc., BioEra Life Sciences Pvt. Ltd., and Ichor Medical Systems. Bio-Rad Laboratories and Thermo Fisher Scientific are the leading players dominating the market owing to their wide product portfolios and strong geographical presence across major markets.
For More Insights, Read: https://www.newsstatix.com/electroporation-instruments-market-size-share-and-growth-forecast-2023-2030/
Comments
0 comment